ZLAB (Zai Lab) Stock Based Compensation: $63.3 Mil (TTM As of Mar. 2026)


ZLAB Zai Lab Ltd ZLAB
64 GF Score
Price $18.52
GF Value $30.30
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Zai Lab Stock Based Compensation?

Zai Lab ZLAB +0.76% 64 Stock Based Compensation is $63.3 Mil as of Mar. 2026. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.30 (Possible Value Trap). The stock has 8 warning signs investors should review.

Zai Lab's Stock Based Compensation for the three months ended in Mar. 2026 was $13.5 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $63.3 Mil.

Zai Lab Stock Based Compensation Related Terms

Zai Lab Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Zai Lab's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zai Lab Stock Based Compensation Chart

Zai Lab Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.71 61.30 79.63 70.65 65.60

Zai Lab Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.80 16.97 16.92 15.90 13.52
ZLAB
64GF Score
Zai Lab Ltd ZLAB
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zai Lab Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $63.3 Mil.

What does a Stock Based Compensation of $63.3 Mil mean?
Zai Lab (ZLAB) has a Stock Based Compensation of $63.3 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Zai Lab and its competitors.
Is Zai Lab's Stock Based Compensation too high?
Zai Lab's current Stock Based Compensation is $63.3 Mil. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's Stock Based Compensation compare to TYRA and TRVI?
Zai Lab's Stock Based Compensation of $63.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Zai Lab and its competitors. Zai Lab's current Stock Based Compensation is $63.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.30, compared to a current price of $18.52 — trading 38.9% below its estimated fair value. The current Stock Based Compensation is $63.3 Mil. Zai Lab's overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Zai Lab (ZLAB), the current Stock Based Compensation is $63.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zai Lab (ZLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued. The current stock price of $18.52 is trading 38.9% below its estimated GF Value™ of $30.30. GuruFocus considers Zai Lab to be Possible Value Trap.

Key valuation signals for ZLAB:

  • Stock Based Compensation: $63.3 Mil
  • GF Value™: $30.30 vs. price of $18.52 (38.9% below fair value)
  • GF Score™: 64/100 with 8 warning signs

No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zai Lab Business Description

Other Exchanges 09688:Hong Kong1ZLB:Germany
Address 899 Halei Road, Building B, Pudong, Shanghai, CHN, 201203
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score

Get the complete analysis for ZLAB

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.52
Price
$30.30
GF Value